[The regulatory evaluation of tumor-agnostic drugs.]

Abstract excerpt

The transition from the traditional to the mutational model in oncology represents a crucial change, not only from the nosological point of view, since - unlike the traditional one - the new approach is no longer strictly linked to anatomical localization and histology, but also from the point of view of adaptation of the health and regulatory systems to the new paradigm. Agnostic oncology therefore represents a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Medical Oncology
• Share to Mutation
• Share to Neoplasms